Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 5/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.47 |
| ▸ | CDK4 | P11802 | 12/20 | 0.45 |
| ▸ | CCND1 | P24385 | 12/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.45 |
| ▸ | CDK2 | P24941 | 9/20 | 0.45 |
| ▸ | CDK1 | P06493 | 8/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.45 |
| ▸ | TTK | P33981 | 2/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2921103 | 0.90 | PDGFRB (0.41) | PDGFRBPDGFRACDK4CCND1CCNE1 | |
| SCHEMBL2913098 | 0.90 | CDK4 (0.42) | PDGFRBPDGFRACDK4CCND1CCNE1 | |
| SCHEMBL2917536 | 0.89 | CDK1 (0.39) | PDGFRBPDGFRACDK4CCND1CCNE1 | |
| SCHEMBL2917783 | 0.86 | PDGFRB (0.49) | PDGFRBPDGFRACDK4CCND1CCNE1 | |
| SCHEMBL2918434 | 0.82 | CDK4 (0.43) | PDGFRBPDGFRACDK4CCND1CCNE1 | |
| SCHEMBL2922682 | 0.79 | PDGFRB (0.48) | PDGFRBPDGFRACDK4CCND1CCNE1 | |
| SCHEMBL2918733 | 0.77 | IGF1R (0.41) | PDGFRBPDGFRACDK4CCND1CCNE1 | |
| SCHEMBL2918438 | 0.77 | IGF1R (0.46) | PDGFRBPDGFRACDK4CCND1CCNE1 | |
| SCHEMBL2912557 | 0.73 | IGF1R (0.45) | PDGFRBPDGFRACDK4CCND1CCNE1 | |
| SCHEMBL2920763 | 0.73 | JAK2 (0.47) | PDGFRBPDGFRACDK4CCND1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009084695-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | DSTYK, ABL1, EEF2K | PDGFRB 1018/4885PDGFRA 862/4885CDK4 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.